Free Trial

Cytokinetics (CYTK) Competitors

Cytokinetics logo
$51.13 -2.19 (-4.11%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$52.30 +1.18 (+2.30%)
As of 09/12/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CYTK vs. GMAB, VTRS, ASND, RDY, QGEN, BBIO, MRNA, ELAN, VRNA, and ROIV

Should you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include Genmab A/S (GMAB), Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.

Cytokinetics vs. Its Competitors

Genmab A/S (NASDAQ:GMAB) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Genmab A/S has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$3.26B5.47$1.14B$1.9913.98
Cytokinetics$85.74M71.36-$589.53M-$5.10-10.03

Genmab A/S has a net margin of 37.53% compared to Cytokinetics' net margin of -707.17%. Genmab A/S's return on equity of 21.03% beat Cytokinetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Genmab A/S37.53% 21.03% 16.98%
Cytokinetics -707.17%N/A -45.52%

Genmab A/S currently has a consensus target price of $39.25, indicating a potential upside of 41.09%. Cytokinetics has a consensus target price of $75.38, indicating a potential upside of 47.44%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than Genmab A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genmab A/S
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.70
Cytokinetics
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.87

7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 2.7% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Genmab A/S has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.

In the previous week, Cytokinetics had 6 more articles in the media than Genmab A/S. MarketBeat recorded 17 mentions for Cytokinetics and 11 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.32 beat Cytokinetics' score of 1.17 indicating that Genmab A/S is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genmab A/S
7 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cytokinetics
11 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Genmab A/S beats Cytokinetics on 10 of the 16 factors compared between the two stocks.

Get Cytokinetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CYTK vs. The Competition

MetricCytokineticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$6.12B$3.20B$5.87B$10.13B
Dividend YieldN/A2.30%5.68%4.60%
P/E Ratio-10.0321.1774.7225.95
Price / Sales71.36435.60517.56181.72
Price / CashN/A46.6837.5660.44
Price / Book-44.469.6112.156.29
Net Income-$589.53M-$53.29M$3.28B$270.77M
7 Day Performance-3.55%0.13%0.74%3.86%
1 Month Performance38.49%5.61%4.83%4.86%
1 Year Performance-8.50%10.49%60.57%26.11%

Cytokinetics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CYTK
Cytokinetics
4.3907 of 5 stars
$51.13
-4.1%
$75.38
+47.4%
-5.4%$6.12B$85.74M-10.03250Positive News
Insider Trade
GMAB
Genmab A/S
3.8463 of 5 stars
$24.87
-1.0%
$37.60
+51.2%
+5.0%$15.96B$3.26B12.502,682News Coverage
Positive News
VTRS
Viatris
1.4437 of 5 stars
$10.55
+1.3%
$10.40
-1.4%
-15.2%$12.30B$14.12B-3.6432,000
ASND
Ascendis Pharma A/S
3.2007 of 5 stars
$194.27
+0.2%
$243.36
+25.3%
+71.8%$11.89B$393.54M-37.651,017Positive News
RDY
Dr. Reddy's Laboratories
2.477 of 5 stars
$14.20
-0.1%
$16.95
+19.4%
-8.7%$11.85B$3.81B21.5127,811Positive News
QGEN
Qiagen
4.4749 of 5 stars
$46.53
+0.9%
$49.69
+6.8%
+2.2%$10.34B$2.04B27.495,765
BBIO
BridgeBio Pharma
4.4516 of 5 stars
$51.76
-1.5%
$62.18
+20.1%
+90.0%$9.89B$235.81M-12.66400Analyst Forecast
MRNA
Moderna
4.47 of 5 stars
$24.09
-1.6%
$42.88
+78.0%
-66.3%$9.37B$3.06B-3.205,800Trending News
ELAN
Elanco Animal Health
2.6241 of 5 stars
$18.38
-0.4%
$17.33
-5.7%
+28.7%$9.13B$4.48B21.379,000Positive News
High Trading Volume
VRNA
Verona Pharma PLC American Depositary Share
2.1853 of 5 stars
$105.91
+0.0%
$109.00
+2.9%
+254.9%$8.67B$221.67M-106.9830Positive News
ROIV
Roivant Sciences
3.1685 of 5 stars
$11.93
-0.1%
$16.50
+38.3%
+16.2%$8.15B$29.05M-17.04860News Coverage
Options Volume

Related Companies and Tools


This page (NASDAQ:CYTK) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners